Evidence map›Paper›PMID 41296502›Full record

SynthesisESC heart failure2025

Economic burden of heart failure in Europe: A systematic review of costs and cost-effectiveness.

Josep Darbà, Meritxell Ascanio, Antonio Rodríguez, Sarah J Charman, Nduka C Okwose, Renae J Stefanetti, Amy Groenewegen, Annamaria Del Franco, Maria Tafelmeier, Andrej Preveden and 27 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Palliative Care in Advanced Heart Failure.Current heart failure reports · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Josep DarbàDepartment of Economics, Universitat de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0003-2371-0999
Meritxell AscanioBCN Health Economics and Outcomes Research S. L, Travessera de Gràcia, Barcelona, Spain.
Antonio RodríguezBCN Health Economics and Outcomes Research S. L, Travessera de Gràcia, Barcelona, Spain.
Sarah J CharmanTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Nduka C OkwoseClinical Sciences and Translational Medicine Research Theme, Research Centre for Health and Life Sciences, Institute of Health and Wellbeing, Coventry University, Coventry, UK.
Renae J StefanettiNewcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Amy GroenewegenDepartment of General Practice & Nursing Science, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.
Annamaria Del FrancoCareggi University Hospital, Florence, Italy.
Maria TafelmeierDepartment of Internal Medicine II, University Medical Centre Regensburg, Regensburg, Germany.
Andrej PrevedenFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Amy S FullerClinical Sciences and Translational Medicine Research Theme, Research Centre for Health and Life Sciences, Institute of Health and Wellbeing, Coventry University, Coventry, UK.
Fatima BanoClinical Sciences and Translational Medicine Research Theme, Research Centre for Health and Life Sciences, Institute of Health and Wellbeing, Coventry University, Coventry, UK.
David R SinclairPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Duncan EdwardsPrimary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Anne P NelissenDepartment of General Practice & Nursing Science, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.
Petros N MalitasPKNM Solutions Sàrl, Chemin Des Vignes, 2, Colombier (VD), CH - 1114 Commune D'Echichens, Vaud, Switzerland.
Aikaterini ZisakiPKNM Solutions Sàrl, Chemin Des Vignes, 2, Colombier (VD), CH - 1114 Commune D'Echichens, Vaud, Switzerland.
Zoran BosnićFaculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia.
Petar VračarFaculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia.
Alessandra FornaroCareggi University Hospital, Florence, Italy.
Fausto BarloccoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Dimitris FotiadisDepartment of Biomedical Research, Foundation for Research and Technology Hellas, Heraklion, Greece.
Prithwish BanerjeeClinical Sciences and Translational Medicine Research Theme, Research Centre for Health and Life Sciences, Institute of Health and Wellbeing, Coventry University, Coventry, UK.
Guy A MacGowanNewcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Oscar FernandezNewcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
José Luis ZamoranoHospital Universitario Ramón y Cajal, Madrid, Spain.
Marta Jimenez-Blanco BravoHospital Universitario Ramón y Cajal, Madrid, Spain.
Lars S MaierDepartment of Internal Medicine II, University Medical Centre Regensburg, Regensburg, Germany.
Iacopo OlivottoDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Massimo MilliAzienda ASL Toscana Centro, Florence, Italy.
Frans H RuttenDepartment of General Practice & Nursing Science, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.
Jonathan MantPrimary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Lazar VelickiFaculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Petar M SeferovicDepartment of Cardiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Nenad FilipovicBioengineering Research and Development Center, BioIRC, Kragujevac, Serbia.
Djordje G JakovljevicTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
STRATIFYHF investigators

Funding

European Union's Horizon Europe research and innovation programme 101080905Federal Department of Economic Affairs, Education and Research (EAER)Finance Research and Innovation/European Framework Programmes, for Suisse ConfederationNational Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC)State Secretariat for Education, Research and Innovation (SERI)UK Research and Innovation 10073472
6 · The paper itself

Abstract

Heart failure (HF) affects over 64 million individuals worldwide and is a major cause of hospitalization and mortality, particularly among older adults. In Europe, HF imposes a significant and growing economic burden. This systematic review aimed to evaluate the economic impact of HF diagnosis, treatment and management across European healthcare systems. A systematic literature search was conducted using PubMed, Cochrane Library and Econlit databases including the terms 'heart failure' AND 'costs' OR 'cost of illness' OR 'cost analysis' OR 'economic burden' OR 'cost effectiveness' OR 'primary care' OR 'secondary care'. Studies published between January 2000 and January 2024 were included. A total of 49 studies were included: 17 on resource use, 11 on costs, 15 on resource use and costs, 1 on costs and cost-effectiveness, and 5 on resource use, costs and cost-effectiveness. Hospitalizations and medication use were the most frequently reported resource parameters. Annual HF-related costs varied widely across countries, ranging from €613 to €22,647 per patient. Hospitalizations represented the primary cost driver, accounting for 15% to 92% of total HF costs. Cost-reduction strategies included multidisciplinary care, telemonitoring and pharmacologic interventions. Several disease management programmes reduced hospital admissions and emergency visits. Cost-effectiveness analyses supported the use of certain HF therapies, with incremental cost-effectiveness ratios ranging from €1490 to €9406 per QALY gained. F imposes a substantial economic burden in Europe, largely driven by hospitalizations. Cost-effective interventions such as remote monitoring and integrated care programmes can reduce this burden. Broader adoption of these strategies may improve outcomes and optimize resource allocation across healthcare systems.

Indexed as

Cost of IllnessHealth Care CostsHeart FailureCost-Benefit AnalysisEuropeHospitalizationHumanscost effectivenesseconomic burdenhealthcare costsheart failureresource utilization

Identifiers

PMID41296502
PMCPMC12719840

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.